NCT00559897 is a Phase 2 clinical trial of 3'-deoxy-3'-[18F]FLT in Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Who is sponsoring NCT00559897?

NCT00559897 is sponsored by Barbara Ann Karmanos Cancer Institute.

What drugs are being tested in NCT00559897?

Interventions in NCT00559897: 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography.

What condition does NCT00559897 study?

NCT00559897 studies Lung Cancer, Metastatic Cancer.

Is NCT00559897 still recruiting?

NCT00559897 is currently terminated. Last updated 26 January 2015.

Are results published for NCT00559897?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2015-01-26 · How we verify

NCT00559897

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study Evaluating the Effect of Zolendronic Acid on Standardized Uptake Value (SUV) on FLT PET Scans in Non-Small Cell Lung Cancer (NSCLC)

Terminated Phase 2 Results posted Last updated 26 January 2015

What this trial tests

Phase 2 trial testing 3'-deoxy-3'-[18F]FLT in Lung Cancer in 6 participants. Terminated before completion.

Timeline

1 March 2008

Primary endpoint
1 April 2010

1 April 2011

Quick facts

Lead sponsor	Barbara Ann Karmanos Cancer Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	6
Start date	1 March 2008
Primary completion	1 April 2010
Estimated completion	1 April 2011
Sites	1 location across United States

Drugs / interventions tested

3'-deoxy-3'-[18F]FLT
Single photon emission computed tomography

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Metastatic Cancer — all drugs for Metastatic Cancer →

Sponsor

Barbara Ann Karmanos Cancer Institute

Who can join

18 and older, any sex, with Lung Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

PET Response Rate
Time frame: FLT PET scan will be done 6-8 days after the dose of zoledronic acid

Sponsor's own description

RATIONALE: A positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where tumor cells are found. This study is looking at whether the drug zoledronic acid interferes with the ability of a PET scan to find tumor cells. PURPOSE: This phase II trial is studying how well positron emission tomography works when given together with zoledronic acid in finding tumor cells in patients with advanced non-small cell lung cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Barbara Ann Karmanos Cancer Institute trials

Trials by the same sponsor.

NCT07343297 — Ask Questions About Clinical Trials · NA · not yet recruiting
NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
NCT07098299 — Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies · Phase 1 · recruiting
NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00559897 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute
Last refreshed: 26 January 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00559897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing